<DOC>
	<DOCNO>NCT02548390</DOCNO>
	<brief_summary>This open-label , Phase I/Ib , dose escalation study intravenous RXDX-107 administer subject advance solid tumor . The study design explore safety , maximum tolerate dose ( MTD ) , pharmacokinetics , pharmacodynamics , preliminary clinical activity RXDX-107 define recommend Phase 2 dose ( RP2D )</brief_summary>
	<brief_title>Study Intravenous RXDX-107 Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Confirmed relapsed refractory locally advance metastatic solid cancer standard therapy consider appropriate , standard therapy consider intolerable . 2 . &gt; 18 year age . 3 . ECOG performance status 0 1 . 4 . Life expectancy least 3 month . 5 . Received last dose previous treatment / therapy Day 1 cycle 1 : 28 day cytotoxic chemotherapy , immunotherapy , whole brain radiotherapy , anticonvulsive therapy , stereotactic radiosurgery major surgery 42 day nitrosureas , mitomycin C , liposomal anthracycline 14 day noncytotoxic cancer therapy radiotherapy 6 . Recovered toxic effect ( exclude alopecia ) prior anticancer therapy Grade â‰¤ 1 baseline laboratory value . 7 . Adequate organ function baseline laboratory value 8 . Women childbearing potential must negative serum pregnancy Phase 1b : Patient must measurable disease 1 . Receiving experimental therapy 2 . Known symptomatic brain mets leptomeningeal involvement 3 . Myocardial infarction previous 12 week . Active ischemia uncontrolled cardiac condition angina pectoris , significant cardiac arrhythmia require therapy , uncontrolled hypertension , CHF . 4 . Another concurrent illness would preclude study conduct assessment , uncontrolled : medical condition , active infection , risk bleeding , diabetes mellitus , pulmonary disease , alcoholic liver disease , primary biliary cirrhosis . 5 . Malignancy within 3 year active disease require treatment target cancer . The exception prostate cancer ( Gleason grade &lt; 6 normalize PSA level ) , treat situ cervical , breast carcinoma , squamous basal cell skin cancer . 6 . Any condition may compromise ability give write informed consent comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Phase 1/1b</keyword>
	<keyword>open-label</keyword>
	<keyword>dose-escalation</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>solid tumor</keyword>
	<keyword>metastatic cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>nano formulation</keyword>
	<keyword>alkylator</keyword>
</DOC>